Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases including Alzheimer's disease ("AD") and Parkinson's disease ("PD"), announced it will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT, followed by a live question-and-answer session. Founder, President and CEO Maria Maccecchini, Ph.D., will discuss recent progress, ongoing clinical programs and upcoming milestones, including the fully enrolled pivotal Phase 3 AD trial, with top-line data and regulatory submissions expected in 2027. The company also plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data, while its PD open-label study is underway and discussions continue regarding initiation of a Parkinson's disease dementia program.
This announcement is significant because it provides investors and stakeholders with a clear timeline for key data readouts and regulatory submissions, which could be pivotal for the company's future. The webinar is an opportunity for the investment community to gain insights into the company's strategic direction and the progress of its lead candidate, buntanetap. Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The company's focus on Alzheimer's and Parkinson's diseases addresses a significant unmet medical need, as these conditions affect millions worldwide and currently have limited treatment options. The upcoming Phase 3 AD trial data, expected in 2027, could be a major catalyst for the company. Additionally, the initiation of the AD open-label study will provide long-term safety data, which is crucial for regulatory approval and market acceptance. The ongoing PD open-label study and potential initiation of a Parkinson's disease dementia program further expand the company's pipeline and potential market opportunities.
Investors interested in learning more about Annovis Bio's progress and future plans are encouraged to participate in the webinar. The company's commitment to transparency and communication is evident through this proactive update. For more information about Annovis Bio, visit its website at www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. The full press release can be viewed at https://ibn.fm/mls3F.
